27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Our results depict that 5 Hz rTMS of the bilateral cerebellum is a promising, non-invasive treatment of cognitive dysfunction in AD patients. 4 key findings →
Participants: 27 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This initial report describes the ongoing 4-year longitudinal study and provides baseline results, which confirm the feasibility of obtaining home-based clinical information via mail or telephone. 2 key findings →
Design: longitudinal study Participants: 644 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Short-term administration of latrepirdine is well tolerated in patients with HD and may have a beneficial effect on cognition. 3 key findings →
Participants: 46 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Tacrine stabilizes or improves specific behavioral deficits and symptoms in AD. 1 key finding →
Participants: 181 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Patients and their study partners who were enrolled in a clinical trial supported proxy consent both for themselves and as a matter of policy. 2 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
At 6 mo, the n-3 FA group displayed marked increases in DHA and EPA plasma concentrations (2.6- and 3.5-fold), as well as decreased methylation in 2 out of 4 CpG sites ( P r = -0.25, P = 0.045; and r = -0.26, P = 0.041, respectively), but not to changes in plasma DHA concentration, and were not related to apolipoprotein E-4 allele frequency. 4 key findings →
Participants: 63 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Finding positive gains reduces depressive symptoms and burden and promotespsychological well-being primarily through enhancing self-efficacy in controlling upsetting thoughts. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Reduction of verbal repetition was set as a treatment goal in 44% (n = 57) of randomized patients. 3 key findings →
Participants: 57 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
These findings have implications for clinical practice and suggest that presence of a caregiver may be an important modifying variable on patient outcomes to examine in future research. 3 key findings →
Design: randomized controlled trial Participants: 210 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Bapineuzumab SC once-monthly did not demonstrate significant treatment difference over placebo on cerebral amyloid signal at one year but was well-tolerated. 3 key findings →
Participants: 146 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This sample of the older general public generally supported a policy of surrogate consent for AD research at baseline. 1 key finding →
Design: randomized controlled trial Participants: 503 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Of 4413 individuals (mean [SD] age, 71.27 [4.66] years, 2617 women [59.3%]), mean Aβ-PET was elevated in individuals with history of memory impairment in both parents (n = 455; mean [SD] standardized uptake value ratio [SUVR] = 1.12 [0.19]; Wilcoxon P = 1.1 × 10-5) and in those with only maternal history (n = 1772; mean [SD] SUVR = 1.10 [0.19]; Wilcoxon P = 2.70 × 10-5) compared with those with only paternal history (n = 632; mean [SD] SUVR = 1.08 [0.18]; Wilcoxon P = 1.1 × 10-5) or no family history (n = 1554; mean [SD] SUVR = 1.08 [0.19]; Wilcoxon P = 1.1 × 10-5). 3 key findings →
Design: cross-sectional Participants: 455 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This study suggests that initiation of a low dose of antihypertensive treatment does not significantly increase the risk of OH in patients with mild-to-moderate Alzheimer disease. 5 key findings →
Design: randomized controlled trial Participants: 255 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Cognitive performance in mild AD improved following tACS, with increased FC within cortical networks and between the hippocampus and specific cortical regions. 2 key findings →
Design: randomized controlled trial Participants: 23 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
One hundred two (37.9%) participants were amyloid positive. 3 key findings →
Design: randomized controlled trial Participants: 269 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This study shows that Hcy levels could modify the association between red blood cell n-3 PUFA and executive function. 2 key findings →
Participants: 1,680 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Choline alfoscerate exhibits additional cognitive improvement in both cognitive and noncognitive domains, supporting the findings of the ASCOMALVA trial. 2 key findings →
Participants: 119 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of 44 844 patients invited to the APT Webstudy, the mean (SD) age was 64.7 (10.1) years, 25 447 (56.8%) were women, 25 044 (55.8%) had Medicaid insurance, 11 347 (25.3%) were Hispanic/Latino, 9526 (21.2%) were non-Hispanic Asian, 6044 (13.5%) were non-Hispanic Black, and 12 109 (27%) were non-Hispanic White. 2 key findings →
Participants: 844 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The 59 recruiting sites for the Alzheimer's Disease Neuroimaging Initiative (ADNI). 4 key findings →
Design: cohort study Participants: 177 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 1005 amyloid-positive participants, 24.6% were eligible for lecanemab and 28.0% for donanemab (9.1% and 10.3% of the initial sample). 5 key findings →
Participants: 2,726 Evidence: low
Full summary, score breakdown and related studies → Original source
Thirty-three patients were included: the revaluation of anti-dementia treatment led to 22 discontinuations and 11 continuations. 5 key findings →
Design: longitudinal study Participants: 14 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In this national case-control study of nursing home residents with ADRD receiving hospice care, initiation of benzodiazepine or antipsychotic use was associated with increased 180-day mortality. 5 key findings →
Design: case-control Participants: 139,103 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Research into dementia prevention is of paramount importance if the dementia epidemic is to be halted. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Atorvastatin therapy may be of benefit in the treatment of mild-to-moderately affected AD patients, but the level of benefit produced may be predicated on earlier treatment, an individual's apolipoprotein E genotype or whether the patient exhibits elevated cholesterol levels. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The protective effect of statin on Alzheimer disease (AD) is still controversial, probably due to the debate about when to start the use of statin and the lack of any large-scale randomized evidence that actually supports the hypothesis. 2 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →